Business Wire

MED™ 3D Printed Pharmaceutical Product Receives IND Clearance From the US FDA

9.2.2021 15:00:00 EET | Business Wire | Press release

Share

Triastek, Inc. (“Triastek”), a pharmaceutical company specializing in 3D printing of drug products, announced today that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) 505(b)(2) application for its first 3D printed drug product – T19, indicated for the treatment of rheumatoid arthritis (RA). Developed in-house, Triastek has global intellectual property rights to the T19 3D printed formulation.

The novel design made possible by 3D printing allows T19 to function as a chronotherapeutic drug delivery system, targeting the circadian nature of RA symptoms. Patients take T19 at bedtime with the tablet releasing drug in a delayed manner such that the blood concentration peaks in the early morning hours when the symptoms of pain, joint stiffness and dysfunction are most acute. T19 utilizes Melt Extrusion Deposition (MEDTM) 3D printing technology to achieve three-dimensional tablet structures that allow precise control of drug release to achieve the desired target PK in the human body, with the goal of addressing these unmet needs of RA patients.

It is predicted that by 2025, the global RA market will reach $30.7 billion (CAGR 4.5%), with T19's unique chronotherapeutic delivery system providing patients with a much-needed therapeutic option. Informa, a pharmaceutical market intelligence consulting company, suggests that T19 can capture substantial portion of RA market in China and the U.S after launch.

Triastek plans to apply for IND approval in China later this year, followed by applications in Japan and Europe. The New Drug Application (NDA) of T19 is expected to be filed to the U.S. FDA in 2023.

Following T19, Triastek has developed 505(b)(2) product portfolio to meet specific clinical needs and improve the outcomes of drug therapy using MEDTM 3D printing technology.

Background on MEDTM 3D printing technology

The MEDTM 3D printing technology platform encompasses digital pharmaceutical dosage form design, an efficient product development approach and automated intelligent manufacturing. Tablets can be constructed to have sophisticated shapes and internal geometric structures that serve to modulate the onset time, kinetics, duration, and mode of drug release with great predictability and reproducibility. This customizable release kinetics can help to enhance therapeutic effects, lower side effects, improve compliance, and efficiently develop pharmaceutical products in different stages.

Triastek has also developed a novel pharmaceutical product development method, 3D printing formulation by design (3DFbD®), to circumvent the trial and error or experience oriented traditional formulation development process. This methodology greatly improves the efficiency and success rate of drug product development, thereby reducing development time and costs. Moreover, integration of real-time Process Analytical Technology (PAT) in the continuous MEDTM 3D printing manufacturing system enables continuous monitoring of the manufacturing process to assure production quality, reduce manufacturing cost, and to provide convenience for regulatory monitoring.

In April 2020, Triastek’s MEDTM 3D printing was accepted into the FDA Emerging Technology Program (ETP). FDA recognized MEDTM 3D printing based on the following features: (a) the proposed use of a MEDTM based 3D technology to manufacture modified release solid oral dosage form, and (b) a fully automated process using PAT and feedback controls.

Dr. Senping Cheng, co-founder and CEO of Triastek, said, “Triastek is committed to improving the efficiency of formulation development, enhancing the effects of drug products, and ensuring the quality of drug delivered to patients by using 3D printing technology platform. The FDA IND clearance of T19 is an important milestone in the development and application of MEDTM 3D printing technology.”

Dr. Xiaoling Li, co-founder and CSO of Triastek, said, “We believe that the MEDTM 3D printing technology will be the enabler for digital pharmaceutical product development and intelligent drug manufacturing. Triastek will work with any interested parties to take advantage of this platform technology for developing pharmaceutical products with better clinical value and higher product quality.”

About Triastek, Inc.

Triastek is an international pharmaceutical company founded in July 2015 by Dr. Senping Cheng, who has entrepreneurial experience both in China and the United States, and Dr. Xiaoling Li, an American pharmaceutical scientist and educator. It is committed to building a novel 3D printing pharmaceutical technology platform for dosage form design, product development, and intelligent manufacturing. In-house product development and co-development with partners are two main business models; in terms of co-development, Triastek has reached a number of agreements with top multinational and Chinese pharmaceutical companies. Triastek’s mission is to be a global leader in the field of 3D printing pharmaceuticals and establish a new era of intelligent pharmaceutical manufacturing.

For more information, please visit Triastek’s website at https://www.triastek.com/indexen.html

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Business Development and Public Relations:
Eric Tsai
Business Development Director
etsai@triastek.com
M: +86 18502118450

Investor Relations:
Limin Zhang
Executive Assistant to CEO
lzhang@triastek.com
M: +86 13851775094

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Canada to Join the NATO Innovation Fund to Advance the Local Defence, Security and Resilience Ecosystem21.11.2026 18:00:00 EET | Press release

Canada announced today it is joining the NATO Innovation Fund, becoming the 25th Allied nation to commit to backing deep tech innovation to address the needs of NATO nations. The Government of Canada is committing EUR 64,590,000 (approximately CAD $100 million) to the firm, with the Business Development Bank of Canada (BDC) holding and managing Canada’s investment in the Fund. This brings total commitments to the NATO Innovation Fund to more than EUR 1.1 billion. Canadian membership will give domestic innovators access to patient capital, opportunities to accelerate the adoption of their technology by governments and businesses across the Alliance, a large network of co-investors, and lessons learned from the NIF’s work to date across 24 participating nations. “Canada has the talent, the innovation, and the ambition to be a global leader in defence and security. The NATO Innovation Fund is helping turn that potential into real capabilities by connecting Canadian innovators with the inv

Persona Earns CEN/TS 18099 High Certification for Injection Attack Detection21.11.2026 16:30:00 EET | Press release

Persona, the leading global identity platform, today announced that its Android SDK has earned CEN/TS 18099 High certification for injection attack detection (IAD). High certification is the top level of the European standard. The evaluation was run by CLR CERT, the certification body of Cabinet Louis Reynaud (CLR) Labs. CLR Labs is accredited under ISO/IEC 17025, the international standard for testing laboratories, and it edits CEN/TS 18099. This certificated injection attack detection is available to all Persona customers and can be activated by working with Persona's team. Injection attacks skip the camera entirely. Instead of holding a photo or mask up to a lens, fraudsters use virtual cameras, emulators and tampered devices to feed stolen, manipulated, or AI-generated media straight into the verification flow. To the system, the result looks like a real live capture, and traditional liveness checks aren't built to catch it. "Our customers are facing more sophisticated deepfakes, f

Verlinvest to Facilitate China Resources’ Full Exit From Oatly20.11.2026 23:30:00 EET | Press release

Verlinvest, the global, family-backed consumer-focused evergreen investment company, today announced it has entered into an agreement to acquire China Resources Enterprise, Limited’s (“China Resources”) indirect interests in Oatly Group AB (publ) (Nasdaq: OTLY) (“Oatly”), the world’s original and largest oat drink company. The transaction builds on Verlinvest’s investment in Oatly since 2016 and reinforces its conviction in the company’s long-term potential. A change in strategic direction of state-owned enterprise China Resources informed its decision to fully exit its investment in Oatly. China Resources worked constructively with Verlinvest to identify the best path for it to do so in recognition of the complexity of their joint holding structure. Under the agreement, Verlinvest will acquire China Resources’ indirect interests in Oatly’s equity and convertible instruments that are currently held through Verlinvest and China Resources’ joint venture vehicle, Nativus Company Limited.

Picsart Opens the AI Behind Its Platform to Developers & Businesses20.11.2026 21:54:00 EET | Press release

Picsart, the AI media production and distribution platform backed by Sequoia Capital and SoftBank Vision Fund 2, today launched Picsart Platform - a multimodal creative AI hub that gives developers the technology behind the platform used by more than 100 million people each month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261120520968/en/ Picsart Opens the AI Behind Its Platform to Developers & Businesses. They can now build their own video, audio, image features using 250+ models from 30+ providers, alongside Picsart's own editing models, through one API, CLI or MCP server. As new video and image models launch every few weeks, managing separate APIs, API keys, and billing systems creates a fragmented ecosystem. By offering unified access to creative tools, Picsart Platform eliminates fragmentation for all creators, spanning independent developers and corporate marketing teams and studios, by providing access to over 25

NetJets Becomes Official Private Aviation Provider of the Hahnenkamm Races in Kitzbühel20.11.2026 19:45:00 EET | Press release

NetJets, the global leader in private aviation, is delighted to announce its newest partnership with the Hahnenkamm Races in Kitzbühel, Austria, becoming the event's Official Private Aviation Provider. The Hahnenkamm Races are among the most prestigious and celebrated events in world alpine skiing. They attract athletes, business leaders, international guests and winter sports enthusiasts from around the world. Through this partnership, NetJets and the Hahnenkamm Races are aligning two brands renowned for excellence, precision and world-class experiences. The partnership is an exciting addition to NetJets' growing portfolio of premium lifestyle and sporting partnerships, offering Owners unique opportunities to access one of Europe's most iconic winter sporting events. Alongside premium hospitality and unforgettable behind-the-scenes experiences, the collaboration will help create extraordinary moments for Owners, both in the air and on the ground in Kitzbühel. “Kitzbühel is synonymous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye